Phase 2 Readout~quarter
Phase 2 Readout: aficamten
- Company
- CYTOKINETICS INC (CYTK)
- Drug
- aficamten
- Indication
- HCM
Other upcoming events for CYTK
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Afica
Phase 3 ReadoutPhase 3 Topline: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Open-label, Multicenter Trial to Evaluate the Efficacy, Safety, and Tolerabil
Phase 3 ReadoutPhase 3 Topline: A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.